Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38
Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates
Loading...